Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children

Author:

Amlie-Lefond Catherine1,Shaw Dennis W.W.2,Cooper Andrew3,Wainwright Mark S.1,Kirton Adam4,Felling Ryan J.5,Abraham Michael G.6,Mackay Mark T.7,Dowling Michael M.8,Torres Marcela9,Rivkin Michael J.10,Grabowski Eric F.11,Lee Sarah12,Kurz Jonathan E.13,McMillan Hugh J.14,Barry Dwight3,Lee-Eng Jacqueline1,Ichord Rebecca N.15

Affiliation:

1. From the Department of Neurology (C.A.-L., M.S.W., J.L.-E), Seattle Children’s Hospital, WA

2. Department of Radiology (D.W.W.S.), Seattle Children’s Hospital, WA

3. Enterprise Analytics (A.C., D.B.), Seattle Children’s Hospital, WA

4. Department of Neurology, Alberta Children’s Hospital, Calgary, Canada (A.K.)

5. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD (R.J.F.)

6. Department of Neurology, University of Kansas, Kansas City (M.G.A.)

7. Department of Neurology, The Royal Children’s Hospital, Melbourne, VIC, Australia (M.T.M.)

8. Department of Neurology, Children’s Medical Center at Dallas, TX (M.M.D.)

9. Department of Hematology, Cook Children’s Medical Center, Fort Worth, TX (M.T.)

10. Department of Neurology, Boston Children’s Hospital, MA (M.J.R.)

11. Department of Pediatric Hematology-Oncology, Massachusetts General Hospital, Boston (E.F.G.)

12. Department of Neurology, Stanford University, Palo Alto, CA (S.L.)

13. Department of Neurology, Ann & Robert H Lurie Children’s Hospital of Chicago, IL (J.E.K.)

14. Department of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada (H.J.M.)

15. Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia (R.N.I.).

Abstract

Background and Purpose— Data regarding the safety and efficacy of intravenous tPA (tissue-type plasminogen activator) in childhood acute arterial ischemic stroke are inadequate. The TIPS trial (Thrombolysis in Pediatric Stroke; National Institutes of Health grant R01NS065848)—a prospective safety and dose-finding trial of intravenous tPA in acute childhood stroke—was closed for lack of accrual. TIPS sites have subsequently treated children with acute stroke in accordance with established institutional protocols supporting data collection on outcomes. Methods— Data on children treated with intravenous tPA for neuroimaging-confirmed arterial ischemic stroke were collected retrospectively from 16 former TIPS sites to establish preliminary safety data. Participating sites were required to report all children who were treated with intravenous tPA to minimize reporting bias. Symptomatic intracranial hemorrhage (SICH) was defined as ECASS (European Cooperative Acute Stroke Study) II parenchymal hematoma type 2 or any intracranial hemorrhage associated with neurological deterioration within 36 following tPA administration. A Bayesian beta-binomial model for risk of SICH following intravenous tPA was fit using a prior distribution based on the risk level in young adults (1.7%); to test for robustness, the model was also fit with uninformative and conservative priors. Results— Twenty-six children (age range, 1.1–17 years; median, 14 years; 12 boys) with stroke and a median pediatric National Institutes of Health Stroke Scale score of 14 were treated with intravenous tPA within 2 to 4.5 hours (median, 3.0 hours) after stroke onset. No patient had SICH. Two children developed epistaxis. Conclusions— The estimated risk of SICH after tPA in children is 2.1% (95% highest posterior density interval, 0.0%–6.7%; mode, 0.9%). Regardless of prior assumption, there is at least a 98% chance that the risk is <15% and at least a 93% chance that the risk is <10%. These results suggest that the overall risk of SICH after intravenous tPA in children with acute arterial ischemic stroke, when given within 4.5 hours after symptom onset, is low.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3